TGF-β signaling in atherosclerosis and restenosis

30Citations
Citations of this article
8Readers
Mendeley users who have this article in their library.

Abstract

Current theories suggest that atherosclerotic and restenotic lesions result from imbalances between systems that are proinflammatory/fibroproliferative versus the endogenous inhibitory systems that normally limit inflammation and vascular wound repair. Abnormalities in one of the major regulatory pathways, the transforming growth factor-β (TGF-β) system, has been characterized in both animal models and in human lesions and lesionderived cells. TGF-β signaling is capable of regulating many of the key aspects of atherosclerosis and restenosis: inflammation, chemotaxis, fibrosis, proliferation, and apoptosis. There are significant decreases in TGF-β activity in patients with atherosclerosis, and equally important changes in the way cells respond to TGF-β during atherogenesis. Evidence from multiple sources indicates that experimental modulation of TGF-β activity, or TGF-β responses, changes the course of atherosclerosis and intimal hyperplasia. Cells derived from human lesions produce adequate TGF-β levels, but are resistant to the antiproliferative and apoptotic effects of TGF-β. An evolving theory describes TGF-β as a major orchestrator of the vascular repair process, with observable defects in its production, activation, and cellular responses during the atherosclerotic and restenotic processes.

Cite

CITATION STYLE

APA

McCaffrey, T. A. (2009). TGF-β signaling in atherosclerosis and restenosis. Frontiers in Bioscience - Scholar, 1 S(1), 236–245. https://doi.org/10.2741/e23

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free